FRACTURE INCIDENCE REDUCTION AND SAFETY OF TSE-424 (BAZEDOXIFENE ACETATE) COMPARED TO PLACEBO AND RALOXIFENE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-002053-69

Femme Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the efficacy of bazedoxifene acetate 20 mg and bazedoxifene acetate 40 mg in comparison to placebo in reduction of new vertebral fractures in osteoporotic postmenopausal women after 36 months and after 60 months of therapy and after 84 months of therapy. To compare the safety profile of bazedoxifene acetate to placebo.


Critère d'inclusion

  • Reduction of new vertebral fractures in osteoporotic postmenopausal women- Osteoporosis